Concert Pharmaceuticals Stock News

RBC Capital analyst Walter Spracklin lowered the price target for CCL Industries Inc (TSX: CCL.B) (OTC: CCDBF) to C$74 from C$80. The analyst maintained the Outperform rating on the shares.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung - Ch

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK , March 11, 2022 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio of Concert''s CNS therapeutics and accompanying intellectual property. These deuterated compounds represent next-generation therapeutics with applications across several different psychiatric and neurological conditions. Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space. "It is Terran''s goal to become an industry leader in neuropsychiatry by providing a suite of solutions for patients suffering from these diseases, which have not had many, if any, therapeutic options historically. With this acquisition from Concert, we get even closer to our goal," stated Dr.

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2021 Results - Earnings Call Transcript

Concert Pharma press release (CNCE): Q4 GAAP EPS of -$1.01 misses by $0.24.Revenue of $0.01M in-line.“Our team is extremely proud and motivated by our success in enrolling more…

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the fourth quarter of 2021.

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

Concert Pharma (NASDAQ:CNCE) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open.The consensus EPS Estimate is -$0.77 (-11.6% Y/Y) and the consensus…

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) CEO Roger D. Tung sold 6,700 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $3.62, for a total transaction of $24,254.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this []

Marshall Wace LLP reduced its position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 61.2% in the 2nd quarter, Holdings Channel reports. The firm owned 20,455 shares of the biotechnology companys stock after selling 32,226 shares during the period. Marshall Wace LLPs holdings in Concert Pharmaceuticals were worth $86,000 as of its most recent filing with the []

Vanguard Group Inc. lessened its stake in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 10.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,238,016 shares of the biotechnology companys stock after selling 152,050 shares during the period. Vanguard Group Inc. owned 3.85% of Concert []